GI‐Y2, a novel gasdermin D inhibitor, attenuates sepsis‐induced myocardial dysfunction by inhibiting gasdermin D‐mediated pyroptosis in macrophages
GI‐Y2, ein neuer Gasdermin-D-Inhibitor, lindert eine durch Sepsis verursachte Myokarddysfunktion durch Hemmung der Gasdermin-D-vermittelten Pyroptose in Makrophagen
British Journal of Pharmacology · 2025-08 · 182 (15) · 3503-3521
DOI: 10.1111/bph.70040 ↗Auf einen Blick
In Mausmodellen mit Sepsis reduzierte GI‐Y2 die Myokarddysfunktion und die kardiale Entzündung. Der Effekt beruhte auf der Hemmung von GSDMD-vermittelter Pyroptose.
Fragestellung
Wirkt der GSDMD-Inhibitor GI‐Y2 bei sepsisinduzierter Myokarddysfunktion kardioprotektiv?
Methode
Mausmodell mit LPS und Caecal-Ligation-und-Punktion; Behandlung mit GI‐Y2 oder GI‐Y2@MM‐NPs; Beurteilung von Myokarddysfunktion, Pyroptose und Transkriptomik.
Ergebnisse
GI‐Y2 linderte die Myokarddysfunktion und reduzierte die kardiale Entzündung. Es senkte die Makrophagen-Pyroptose und die Makrophagen-vermittelte Kardiomyozyten-Schädigung; ohne GSDMD verschwand der Schutz.
Schlussfolgerung der Autor:innen
Die Autor:innen schließen, dass GI‐Y2 septische Myokardschädigung und -dysfunktion durch gezielte Hemmung von GSDMD, Pyroptose und mitochondrialem Schaden lindert.
Kernaussagen
- GI‐Y2 verringerte Myokarddysfunktion in Sepsis-Mausmodellen
- Die Schutzwirkung war ohne GSDMD aufgehoben
- GI‐Y2@MM‐NPs zeigten in vivo eine Schutzwirkung
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Pharmacology, online erschienen am 31.03.2025. Verfasst von Yiling Mei und 10 weiteren Autor:innen. Beteiligte Einrichtung: The Key Laboratory of Emergency and Disaster Medicine of Wenzhou, Department of Emergency, The First Affiliated Hospital of Wenzhou Medical Universit…. Hauptthemen laut MEDLINE: Pyroptosis, Sepsis, Phosphate-Binding Proteins, Macrophages. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Medical Health Science and Technology Project of Zhejiang Province, Science and Technology Project of Wenzhou, National College Students' Innovative Entrepreneurial Training Plan Program.
Themen: Sepsis
Abstract (Originalsprache)
Background and Purpose Myocardial dysfunction is a significant complication associated with sepsis. However, there are currently no specific and effective treatments available. Inhibiting gasdermin D (GSDMD)‐mediated pyroptosis has shown promise in mitigating sepsis‐induced myocardial dysfunction. The GSDMD inhibitor Y2 (GI‐Y2) has been demonstrated to directly bind to GSDMD. Nonetheless, it remains uncertain whether GI‐Y2 offers a cardioprotective effect in the context of sepsis‐induced myocardial dysfunction. Experimental Approach A mouse model of sepsis was created using lipopolysaccharide (LPS), caecal ligation and puncture. Following treatment with GI‐Y2 or macrophage membrane‐encapsulated GI‐Y2 nanoparticles (GI‐Y2@MM‐NPs), myocardial dysfunction and pyroptosis levels in heart tissues were assessed. Transcriptome sequencing revealed the molecular mechanism of GI‐Y2 in treating septic cardiomyopathy. Key Results We observed that GI‐Y2 alleviated myocardial dysfunction and attenuated cardiac inflammation in mice induced by LPS, caecal ligation and puncture. GI‐Y2 reduced macrophage pyroptosis and attenuated macrophage‐mediated cardiomyocyte injury induced by LPS/nigericin. Concurrently, we confirmed the protective effect of GI‐Y2 against LPS‐induced cardiac dysfunction was abolished in the absence of GSDMD. Additionally, GI‐Y2 attenuated the mitochondrial damage induced by LPS by inhibiting GSDMD in the mitochondria. Furthermore, we developed GI‐Y2@MM‐NPs to enhance the targeting capability of GI‐Y2 towards macrophages in heart tissues and demonstrated its protective effect in vivo . Conclusion and Implications These findings indicate that GI‐Y2 alleviates septic myocardial injury and dysfunction by specifically targeting GSDMD, thereby inhibiting GSDMD‐mediated pyroptosis and mitochondrial damage. Both GI‐Y2 and GI‐Y2@MM‐NPs may serve as promising therapeutic options for addressing septic myocardial dysfunction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Key Laboratory of Emergency and Disaster Medicine of Wenzhou, Department of Emergency, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
- Department of Cardiology and The Key Laboratory of Cardiovascular Disease of Wenzhou, the First Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.
- Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China.
- Department of Cardiology, Ningbo Hangzhou Bay Hospital, Ningbo, Zhejiang, China.
- First School of Medicine, Wenzhou Medical University, Wenzhou, Zhejiang, China.
- Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Huzhou, Zhejiang, China.
Förderung
- Medical Health Science and Technology Project of Zhejiang Province
- Science and Technology Project of Wenzhou
- National College Students' Innovative Entrepreneurial Training Plan Program
- Natural Science Foundation of Zhejiang Province
- Natural Science Foundation of Ningbo Municipality
- National Natural Science Foundation of China
- Science and Technology Bureau of Jiaxing City
- Natural Science Foundation of Ningbo
Zitieren
APA
Mei, Y., Chen, X., Shi, S., Lin, W., Cheng, Z., Fan, X., Wu, W., Han, J., Huang, W., Ye, B., & Dai, S. (2025). GI‐Y2, a novel gasdermin D inhibitor, attenuates sepsis‐induced myocardial dysfunction by inhibiting gasdermin D‐mediated pyroptosis in macrophages. British Journal of Pharmacology, 182(15), 3503-3521. https://doi.org/10.1111/bph.70040
Vancouver
Mei Y, Chen X, Shi S, Lin W, Cheng Z, Fan X, et al. GI‐Y2, a novel gasdermin D inhibitor, attenuates sepsis‐induced myocardial dysfunction by inhibiting gasdermin D‐mediated pyroptosis in macrophages. British Journal of Pharmacology. 2025;182(15):3503-3521. doi:10.1111/bph.70040
BibTeX
@article{Mei2025,
author = {Mei, Yiling and Chen, Xudong and Shi, Si and Lin, Wante and Cheng, Zhenfeng and Fan, Xiaoxi and Wu, Wenqi and Han, Jibo and Huang, Weijian and Ye, Bozhi and Dai, Shanshan},
title = {GI‐Y2, a novel gasdermin D inhibitor, attenuates sepsis‐induced myocardial dysfunction by inhibiting gasdermin D‐mediated pyroptosis in macrophages},
journal = {British Journal of Pharmacology},
year = {2025},
volume = {182},
number = {15},
pages = {3503--3521},
doi = {10.1111/bph.70040}
}
EUVIMED